DexCom, Inc. (DXCM)
- Previous Close
83.35 - Open
84.00 - Bid 78.00 x 200
- Ask 91.73 x 200
- Day's Range
83.50 - 85.74 - 52 Week Range
57.52 - 132.26 - Volume
6,008,093 - Avg. Volume
4,625,809 - Market Cap (intraday)
33.462B - Beta (5Y Monthly) 1.43
- PE Ratio (TTM)
64.17 - EPS (TTM)
1.33 - Earnings Date Jul 23, 2025 - Jul 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
97.68
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
www.dexcom.com/globalRecent News: DXCM
View More
Performance Overview: DXCM
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXCM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXCM
View MoreValuation Measures
Market Cap
33.46B
Enterprise Value
33.34B
Trailing P/E
64.17
Forward P/E
42.55
PEG Ratio (5yr expected)
1.32
Price/Sales (ttm)
8.44
Price/Book (mrq)
14.76
Enterprise Value/Revenue
8.04
Enterprise Value/EBITDA
34.20
Financial Highlights
Profitability and Income Statement
Profit Margin
12.90%
Return on Assets (ttm)
5.97%
Return on Equity (ttm)
23.72%
Revenue (ttm)
4.15B
Net Income Avi to Common (ttm)
535.2M
Diluted EPS (ttm)
1.33
Balance Sheet and Cash Flow
Total Cash (mrq)
2.7B
Total Debt/Equity (mrq)
113.97%
Levered Free Cash Flow (ttm)
509.04M
Research Analysis: DXCM
View MoreResearch Reports: DXCM
View MoreRaising target price to $86.00
DEXCOM INC has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $47.00
TRUPANION INC has an Investment Rating of HOLD; a target price of $47.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetDexcom Earnings: Solid First-Quarter Results Underscore Improvements to Operations
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
RatingPrice TargetDexcom Earnings: Solid First-Quarter Results Underscore Improvements to Operations
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
RatingPrice Target